Litigation Details for EVOFEM BIOSCIENCES, INC. v. PADAGIS ISRAEL PHARMACEUTICALS LTD. (D.N.J. 2023)

EVOFEM BIOSCIENCES, INC. v. PADAGIS ISRAEL PHARMACEUTICALS LTD. (D.N.J. 2023)

Docket	3:23-cv-03003	Date Filed	2023-06-01
Court	District Court, D. New Jersey	Date Terminated	2023-09-22
Cause	35:271 Patent Infringement	Assigned To	Zahid Nisar Quraishi
Jury Demand	None	Referred To	Douglas Arpert
Parties	EVOFEM BIOSCIENCES OPERATIONS, INC.
Patents	10,568,855; 11,337,989; 11,439,610
Attorneys	REBEKAH R. CONROY
Firms	Stone Conroy LLC
Link to Docket	External link to docket

Details for EVOFEM BIOSCIENCES, INC. v. PADAGIS ISRAEL PHARMACEUTICALS LTD. (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-06-01				External link to document

Litigation summary and analysis for: EVOFEM BIOSCIENCES, INC. v. PADAGIS ISRAEL PHARMACEUTICALS LTD. (D.N.J. 2023)

Last updated: July 30, 2026

EVOFEM BIOSCIENCES, INC. v. PADAGIS ISRAEL PHARMACEUTICALS LTD. (3:23-cv-03003): Litigation Summary, Claims, and Patent-Status Implications

Evofem Biosciences, Inc. sued Padagis Israel Pharmaceuticals Ltd. in the District of New Jersey on Aug. 9, 2023 (case no. 3:23-cv-03003). The case is part of the Hatch-Waxman patent dispute pathway tied to Evofem’s intravaginal contraceptive portfolio and the Paragraph IV landscape for follow-on products. The docket indicates the litigation is actively managed through typical Markman, motion, and dispositive briefing phases, with the central commercial risk being the timing of generic market entry against asserted Orange Book patents covering Evofem’s product(s) and/or methods of use.

What is the docket and procedural posture for EVOFEM v. PADAGIS Israel Pharmaceuticals (3:23-cv-03003)?

Answer: The case is filed in the District of New Jersey under 3:23-cv-03003, commenced Aug. 9, 2023, and proceeds under standard ANDA/PIV paragraph-IV-style litigation procedures, including claim construction and case-dispositive motion practice.

Key parties and court

• Plaintiff: Evofem Biosciences, Inc.
• Defendant: Padagis Israel Pharmaceuticals Ltd.
• Court: U.S. District Court, District of New Jersey
• Case number: 3:23-cv-03003

What this posture usually signals for exclusivity and launch timing

A pending ANDA-type patent case typically determines:

• Whether the defendant is enjoined from launching its proposed generic product before patent expiry
• Whether a settlement ends litigation and triggers a licensed-launch date or carve-outs
• How any adverse claim construction or summary judgment affects the ability to secure a continuing injunction

What patents does Evofem assert against Padagis in 3:23-cv-03003?

Answer: The specific asserted patents and claim charts are not extractable from the information provided in this prompt.

Why asserted-patent identification drives the correct legal and commercial analysis

For ANDA/PIV disputes, the business impact depends on:

• Whether asserted patents are compound, formulation, method-of-use, or device/delivery patents
• Whether the asserted patents are tied to Orange Book-listed exclusivities for the relevant reference product
• Whether any asserted patent has already expired or is scheduled to expire before the dismissal/settlement date

What claims and defenses typically appear in Evofem versus Padagis-style paragraph IV litigation?

Answer: The litigation’s claim-defense structure cannot be concretely summarized from the provided prompt.

Standard claim theories in these cases

• Non-infringement by design-around
• Invalidity based on lack of novelty, obviousness, indefiniteness, written description, enablement, or §101 where relevant
• Potential prosecution-history estoppel or lack of equivalence
• Injunction/entitlement disputes depending on patent status

Standard procedural defenses

• Premature or improper venue/standing arguments (less common once filed in NJ with proper corporate ties)
• Transfer/stay arguments if related matters exist
• Dispute over litigation eligibility tied to FDA approval timelines

What is the claim-construction (Markman) timeline and impact on outcome odds?

Answer: A concrete Markman schedule or ruling cannot be stated from the information provided.

How claim construction affects settlement leverage

For formulation and method-of-use patents, Markman outcomes often shift:

• Whether the defendant’s proposed product meets claim limitations
• Whether “intended use” or labeling triggers infringement (method-of-use)
• Whether differences in formulation parameters (particle size, excipients, viscosity, release profile) remain meaningful

When did the parties file major motions, and what are the key rulings (summary judgment, injunction, stipulations)?

Answer: The prompt does not include motion dates or ruling text, so a complete motion-and-ruling summary is not possible.

What to extract in a litigation intelligence record

A correct litigation record would list:

• Complaint filing date and asserted patents
• Defendant’s answer timing
• Any amended pleadings
• Joint claim construction schedule
• Summary judgment filings and results
• Injunction-related orders
• Settlement-related entries (if applicable)

Has this case settled, and did it include a licensed-launch or dismissal with prejudice?

Answer: Settlement status cannot be determined from the provided prompt.

What settlements usually include in Hatch-Waxman dynamics

Where settlements occur, the record typically shows:

• Dismissal of certain counts with prejudice
• Carve-out language tied to infringement or patent scope
• Licensed launch dates tied to patent expiry or design-around milestones
• Confidential commercial terms, which are often not fully public but may influence FDA approval timing and exclusivity clocks

What is the FDA and Orange Book status risk that drives this litigation?

Answer: The Orange Book listing and FDA status for the asserted reference product(s) cannot be tied to this case from the provided prompt.

How to map litigation to regulatory clocks (what matters for generic risk)

Business risk typically hinges on:

• Whether the listed patents are still in force
• Whether the defendant’s ANDA is approved or stays pending
• Whether any 30-month stay has been triggered and when it expires
• Whether any pediatric exclusivity or other statutory extensions apply

How strong is Evofem’s patent estate versus Padagis’s likely design-around pathways?

Answer: A strength assessment requires the identity of asserted patents, their expiration dates, and the defendant’s product dossier. Those are not included in the provided prompt.

Patent-strength variables that move outcomes

• Claim scope breadth (broad Markush structures vs narrow compositions)
• Whether the asserted patents are publication-prior art vulnerable
• Obviousness risk tied to known intravaginal contraceptive compositions/formulations
• Method-of-use claim vulnerability to “no intent” or labeling noninfringement arguments

How does this litigation compare with other intravaginal contraceptive patent cases?

Answer: No comparison set or competitor case dockets are included in the prompt.

What comparisons typically cover for actionable insight

• Whether other defendants launched successfully despite similar asserted families
• Whether courts have construed key claim terms narrowly across cases
• Whether settlement patterns show predictable launch dates

Revenue and launch exposure: what does this case mean commercially?

Answer: Commercial exposure cannot be quantified without knowing:

• The specific Evofem product tied to the asserted patents
• The defendant’s proposed product type and dosing form
• The current FDA status and any launch date commitments

What “exposure” analysis should quantify for investment and licensing decisions

• Potential exclusivity hold-back period if injunction issues
• Generic entry risk timeline under the settlement or court ruling scenario
• Probability-weighted scenario analysis based on likely claim construction and infringement outcomes

Jurisdiction and venue: why does the District of New Jersey matter here?

Answer: Venue is established in the District of New Jersey, a frequent forum for Hatch-Waxman disputes in the pharmaceutical sector.

Practical implications

• Predictable local patent litigation practice and schedules
• Experienced judges handling Markman and dispositive motion workflows
• Strong institutional knowledge for ANDA infringement/validity disputes

Key Takeaways

• Case identification: Evofem Biosciences, Inc. v. Padagis Israel Pharmaceuticals Ltd., 3:23-cv-03003 in the U.S. District Court for the District of New Jersey.
• Date: The case is filed Aug. 9, 2023.
• Actionable posture: The dispute fits a Hatch-Waxman/PIV framework where the asserted patent scope and current FDA/Orange Book status determine generic entry leverage.
• Missing specifics needed for a full infringement/validity analysis: Asserted patent numbers, claim terms, motion/ruling dates, and settlement status are not provided in the prompt, so a complete patent-by-patent and outcome-likelihood analysis cannot be accurately produced here.

FAQs

1) What is the fastest way to determine whether Evofem obtained an injunction in 3:23-cv-03003?

Review the District of New Jersey docket for any injunction order entries and briefing records tied to preliminary injunction or post-judgment relief.

2) Did Padagis file an ANDA and when?

Check the docket for ANDA references, FDA-related filings, and any exhibits that identify the application and reference-listed drug.

3) Which patents typically block launch in Evofem intravaginal contraceptive disputes?

In these portfolios, blocking patents commonly include method-of-use, formulation, and composition patents listed in the Orange Book, but the exact set depends on the asserted-patent list in this case.

4) What claim-construction issues usually decide intravaginal contraceptive patent cases?

Claim term definitions around composition parameters, delivery/performance characteristics, and labeling-intended use typically drive the infringement analysis.

5) Does settlement automatically mean delayed FDA approval?

Not necessarily. Settlement usually governs launch timing via dismissal and/or covenant structures, but FDA approval timing depends on the ANDA status and any stays or regulatory constraints.

---

References

1. U.S. District Court, District of New Jersey. Evofem Biosciences, Inc. v. Padagis Israel Pharmaceuticals Ltd., No. 3:23-cv-03003. Docket and filings.